Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. [electronic resource]
Producer: 20100330Description: 2897-907 p. digitalISSN:- 1522-9645
- Adult
- Aged
- Aged, 80 and over
- Anticoagulants -- therapeutic use
- Antifibrinolytic Agents -- therapeutic use
- Atrial Fibrillation -- complications
- Biomarkers -- metabolism
- Bleeding Time
- Embolism -- prevention & control
- Female
- Fibrin Fibrinogen Degradation Products -- metabolism
- Humans
- Male
- Middle Aged
- Stroke -- prevention & control
- Thrombin -- antagonists & inhibitors
- Vitamin K -- antagonists & inhibitors
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.